Tradestie Institutional Equity Comparison Engine · Market Close Nov 17, 2026

IOVA vs ANNX: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

IOVA Captures Overall Composite Edge (55.0 HOLD vs 43.5 HOLD), While ANNX Leads 3–2 on Growth & Valuation Pillars

IOVA Overall Winner 6-Pillar Tally: IOVA 2 – 3 ANNX (1 Tie) Matrix Metrics: IOVA 5 – 3 ANNX

As of Nov 17, 2026, Iovance Biotherapeutics, Inc. (IOVA) captures the overall head-to-head institutional edge over Annexon, Inc. (ANNX) on higher Unified Composite conviction (55.0/100 HOLD vs. 43.5/100 HOLD) after splitting the core matrix 5–3 (led by Valuation Multiples, Growth & Scale), while ANNX wins 3–2 across the 6-pillar growth and valuation breakdown. IOVA trades at $7.53 (N/M Forward P/E, -60.8% operating margin) versus ANNX at $3.47 (N/M Forward P/E, 0.0% operating margin).

  • Growth vs. Quality Trade-Off: IOVA earns the overall head-to-head edge with a stronger Unified Composite Score (55.0/100 HOLD vs. ANNX 43.5/100 HOLD) and 1.58β · 140% Vol risk profile, whereas ANNX leads top-line expansion (+0.0% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates.
  • Technical & Structure Timing Caution: IOVA is currently in a Breakdown options structure phase (RSI 31.3); meanwhile ANNX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 36.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About IOVA vs ANNX
IOVA NASDAQ Head-to-Head Winner
Iovance Biotherapeutics, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$7.53
-0.26% 1D
Market Cap $3.6B
TTM Revenue $379M
Forward P/E N/M
Beta / 30D Vol 1.58β · 140% Vol
Unified Composite Score
55.0 / 100 HOLD
Tech 53.0 Fund 61.0 Flow 70.0 Mom 60.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 31
RSI-14: 31.3 · SMA20: $10.00 · SMA50: $11.28
ANNX NASDAQ
Annexon, Inc. Common Stock
Pharmaceutical Preparations
$3.47
-2.8% 1D
Market Cap $747.8M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.70β · 63% Vol
Unified Composite Score
43.5 / 100 HOLD
Tech 37.0 Fund 55.0 Flow 72.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -10.2%), weak momentum, RSI 36
RSI-14: 36.3 · SMA20: $3.96 · SMA50: $3.98

6-Pillar Scorecard Institutional Category Breakdown (IOVA 2 – 3 ANNX)

Columns: Metric · IOVA · ANNX
1. Valuation Multiples IOVA
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue 9.4x N/M
2. Growth & Scale IOVA
Revenue Growth (YoY) +80.1% +0.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $379M N/A
Market Cap $3.6B $747.8M
3. Profitability & Quality ANNX
Gross Margin 53.2% N/A
Operating Margin -60.8% 0.0%
Net Profit Margin -58.2% 0.0%
Return on Equity (ROE) -29.1% -130.8%
4. Balance Sheet & Cash Flow ANNX
Cash Generation (TTM) -$216M -$190M
Cash Flow Margin -57.0% N/A
Net Cash / Leverage $13M Net Cash $29M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning ANNX
Options Structure Phase BREAKDOWN BREAKDOWN
Current IV / %ile 117.8% (35th %ile) 569.3% (100th %ile)
Put/Call OI Skew 0.38x (Call-Skewed) 0.09x (Call-Skewed)
OBV Trend / Tech Phase NEUTRAL · Neutral DISTRIBUTION · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: IOVA (5) vs ANNX (3)
Institutional Metric IOVA ANNX Criterion Row Edge
Market Capitalization
Scale
$3.6B $747.8M Larger Scale IOVA
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+80.1% +0.0% Higher Growth IOVA
Operating Margin (TTM)
Profitability
-60.8% 0.0% Higher Margin ANNX
Net Profit Margin
Profitability
-58.2% 0.0% Higher Margin ANNX
Return on Equity (ROE)
Capital Efficiency
-29.1% -130.8% Higher ROE IOVA
52-Week Range Position
Momentum
41% ($2–$15) 18% ($3–$7) Stronger Trend IOVA
Beta / 30D Volatility
Risk Regime
1.58β · 140% Vol 1.70β · 63% Vol Lower Realized Risk ANNX
Unified Institutional Score
Composite Signal
55.0 / 100 (HOLD) 43.5 / 100 (HOLD) Higher Composite IOVA
Trailing 12M Revenue (USD)
Operating Scale
$379M N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
53.2% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 9.4x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$216M ($13M Net Cash) -$190M ($29M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon ANNX +33.54 pp
IOVA: -47.01% · ANNX: -13.47%
3M Horizon IOVA +31.15 pp
IOVA: -5.76% · ANNX: -36.91%
6M Horizon IOVA +146.96 pp
IOVA: +117.63% · ANNX: -29.33%
1Y Horizon IOVA +176.82 pp
IOVA: +204.86% · ANNX: +28.04%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on IOVA vs ANNX. Trailing 12-month operating profitability (IOVA -60.8% vs ANNX 0.0%) and valuation multiples (IOVA N/M vs ANNX N/M Forward P/E) are benchmarked directly in Pillar 4 below.

IOVA ADR TTM Benchmark FX-Normalized USD
TTM Revenue$379M
Gross Margin53.2%
Op. Margin-60.8%
ROE / Fwd P/E-29.1% · N/M
ANNX ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-130.8% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
IOVA BREAKDOWN
34d in phase · OBV NEUTRAL
Current IV 117.8%
IV Percentile 35th %ile
Put/Call OI Skew 0.38x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact IOVA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
ANNX BREAKDOWN
88d in phase · OBV DISTRIBUTION
Current IV 569.3%
IV Percentile 100th %ile
Put/Call OI Skew 0.09x (Call-Skewed)
IV Regime Extreme (>80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact ANNX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
LIVE OPTIONS CHAIN · T+5 TRADING DAY HORIZON Spot $7.55 · IV 80.1%

IOVA Simulated 5-Day Option Payoffs vs. Owning 100 Shares ($755)

Compare $755 in 100-share capital outlay against risk-defined 5-day vertical spreads, put-wall income, and 3-leg structures at 80.1% ATM IV.

5-DAY BULLISH SWING Liq C

Nov 27 $7.5 / $8.5 Bull Call Spread

Buy 2x $7.5C · Sell 2x $8.5C · 11d

Net Entry $70 Debit
T+5d @ +5% Move +$21 (+30%)
Max Risk / Buffer $70 Capped
5d Edge & Liquidity 0.6x R:R · Liq C
Simulate 5-Day Payoff →
5-DAY DOWNSIDE SPREAD Liq C

Dec 4 $8 / $7 Bear Put Spread

Buy 3x $8P · Sell 3x $7P · 18d

Net Entry $78 Debit
T+5d @ -5% Drop +$73 (+94%)
Max Risk / Buffer $78 Capped
5d Edge & Liquidity 1.7x R:R · Liq C
Simulate 5-Day Payoff →

Simulated T+5 trading day payoffs use live option midpoints, bid-ask spread adjustments, and implied volatility skew for educational scenario modeling only — not personalized investment advice. Options involve substantial risk.

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
IOVA Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $3.6B market capitalization and -60.8% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
ANNX Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $747.8M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ IOVA vs ANNX Key Questions & Quantitative Answers

As of Nov 17, 2026, Iovance Biotherapeutics, Inc. (IOVA) captures the overall head-to-head institutional edge over Annexon, Inc. (ANNX) on higher Unified Composite conviction (55.0/100 HOLD vs. 43.5/100 HOLD) after splitting the core matrix 5–3 (led by Valuation Multiples, Growth & Scale), while ANNX wins 3–2 across the 6-pillar growth and valuation breakdown. IOVA trades at $7.53 (N/M Forward P/E, -60.8% operating margin) versus ANNX at $3.47 (N/M Forward P/E, 0.0% operating margin). Growth vs. Quality Trade-Off: IOVA earns the overall head-to-head edge with a stronger Unified Composite Score (55.0/100 HOLD vs. ANNX 43.5/100 HOLD) and 1.58β · 140% Vol risk profile, whereas ANNX leads top-line expansion (+0.0% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: IOVA is currently in a Breakdown options structure phase (RSI 31.3); meanwhile ANNX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 36.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

IOVA leads the Growth & Scale pillar: IOVA posts +80.1% YoY revenue growth and +0.0% YoY earnings growth on $379M TTM revenue (53.2% gross margin, -60.8% operating margin), compared with ANNX at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, IOVA generates $379M in USD-normalized revenue versus N/A for ANNX. In operating R&D and SG&A reinvestment, IOVA deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for ANNX.

IOVA screens cheaper on headline valuation multiples. IOVA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 9.4x EV/Revenue (-57.0% FCF margin), whereas ANNX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against IOVA (-29.1% ROE) versus ANNX (-130.8% ROE) capital efficiency.

In options market volatility and institutional positioning, IOVA carries 117.8% implied volatility (35th %ile, Balanced (25th–60th %ile)), a 0.38x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.58β · 140% Vol realized risk). By comparison, ANNX carries 569.3% implied volatility (100th %ile, Extreme (>80th %ile)), a 0.09x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.70β · 63% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 17, 2026. For educational research only; not investment advice.